, Tracking Stock Market Picks
Enter Symbol:

up 0.16 %

LEXICON PHARMACEUTCL (LXRX) rated Outperform with price target $26 by Wedbush

Posted on: Monday,  Nov 9, 2015  4:25 PM ET by Wedbush

Wedbush rated Outperform LEXICON PHARMACEUTCL (NASDAQ: LXRX) on 11/09/2015. Previously Wedbush rated Outperform LEXICON PHARMACEUTCL (NASDAQ: LXRX) on 04/26/2011.,
when the stock price was $12.11. Since then, LEXICON PHARMACEUTCL has gained 0.17% as of 01/04/2016's recent price of $12.13.
If you would have followed the previous Wedbush 's recommendation on LXRX, you would have gained 0.16% of your investment in 1714 days.

Lexicon Pharmaceuticals, Inc. (Lexicon), is a biopharmaceutical company focused on discovering and developing treatments for human disease. The Company uses its proprietary gene knockout technology to identify and develop new drugs. In its Genome5000 program, Lexicon is utilizing its knowledge of the function of nearly 5,000 genes to identify a portfolio of drug targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a diverse pipeline of drug targets behind its clinical programs with many compounds and antibodies in preclinical research. Lexicon is conducting clinical trials for four drug candidates, with its most advanced program in Phase II clinical trials.

Wedbush is Headquartered in Los Angeles, California with over 90 offices and more than 125 correspondent offices, our commitment to providing relentless, customized service is the foundation of our consistent growth. We deliver superior investment ideas and products through exceptional customer care, financial security, continuity and advanced technology.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/9/2015 4:25 PM Buy
as of 8/27/2015
1 Week up  6.59 %
1 Month up  49.56 %
3 Months up  71.57 %
1 YTD down  -3.73 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/26/2011 9:25 AM Buy
12.11 21.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy